



Office of Justice Programs

2026 Medication-Assisted Substance Use Treatment Grant Program

Fiscal Year 2025-2026 Solicitation

Please Note: Applications are *only* accepted through PCCD's Egrants system. Applicants must register in Egrants prior to submitting an application. Applicants are strongly encouraged to familiarize themselves with the Egrants system and allow adequate time to prepare and submit an application.

Prior to starting an application in Egrants, your agency must be registered in Egrants, and at least two individuals from your agency must register as Egrants users and have Egrants user roles for your agency.

Every agency must also have at least one person with the e-signature role in Egrants.

Please refer to the [Getting Started in Egrants](#) page on our website for Egrants registration information and guides.

Release Date:

December 4, 2025

Egrants Application Deadline:

First Round: January 13, 2026

Second Round: April 16, 2026

This funding guideline contains information not appearing in the Egrants application. Applicants are advised to review this document and refer to it while completing your Egrants application.

Questions concerning this funding announcement may be directed to PCCD staff. For any program-related questions, contact Jennifer Bowser at (717) 257-6255 or jennbowser@pa.gov. For any fiscal or budgetary questions, contact Crystal Lauver at (717) 265-8525 or crlauver@pa.gov.

For any technical or system questions, contact and ask for the Egrants Help Desk at (717) 787-5887 or (800) 692-7292, or by emailing RA-eGrantsSupport@pa.gov.

PENNSYLVANIA COMMISSION ON CRIME AND DELINQUENCY
Office of Justice Programs

Funding Stream: Act 80

TABLE OF CONTENTS

Basic Funding Anouncement Guidelines	3
1. Overview	4
2. Funding Availability	4
3. Project Dates	4
4. Eligible Applicants	5
5. Eligible Program Activities and Expenses	5
6. Ineligible Program Activities and Expenses	6
7. Required Egrants Sections/Documents	6
8. Application Procedures	6
9. Required Attachments	9
10. Performance Measures	9
11. Competitive Bidding/Sole Source Procurement	10
12. Administrative Requirements	11
a. Egrants Agency and User Registration	11
b. Fiscal Accountability	11
c. Time and Effort Reporting	11
d. Grant Payments	11
e. Federal Transparency Act Certification	11
f. Reporting Requirements	11
g. UCR Reporting	11
13. PCCD Contact Information and Resources	11
14. Submission Information	12
15. Appendix A - Maximum County Allocations	13
16. Appendix B - Quarterly Report	14

PENNSYLVANIA COMMISSION ON CRIME AND DELINQUENCY
Office of Justice Programs

Funding Announcement Title: 2026 Medication-Assisted Substance Use Treatment Grant Program

Funding Stream: Act 80

Submission Requirements for Applications:

- **Due Date** – Applications must be submitted electronically through PCCD's Egrants system and will be reviewed in two rounds as received on **Tuesday, January 13, 2026**, and **Thursday, April 16, 2026**. The first round of applications will include all applications received by 11:59 PM on January 13, 2026, which will be presented for consideration at the March 11, 2026, Commission meeting. The second round of applications will include all applications received between January 14, 2026, and the final submission deadline of 11:59 PM on April 16, 2026. The second round of applications will be presented for consideration at the June 10, 2026, Commission meeting.
- **Technical Assistance** – Grant application and administrative guides can be accessed on [PCCD's website](#). Applicants are strongly encouraged to review the application and administrative guides before calling the Egrants Help Desk for assistance. The Egrants Help Desk is available to assist with technical or system questions Monday through Friday, 8:00 AM to 4:00 PM, and may be reached by calling (717) 787-5887 or (800) 692-7292, or by emailing RA-eGrantsSupport@pa.gov.
- **Egrants Submission** – An application submitted in Egrants by the deadline is not considered complete until the application has been electronically signed in Egrants, and PCCD has received any required documents. Successful applications will be presented for consideration at the March 11, 2026, and June 10, 2026, Commission meetings.
- **Administrative Rejection** – An application that does not meet all the listed requirements in this funding announcement may be administratively rejected.
- **Corrections** – If PCCD returns an application for corrections, the final application (including all corrections and required documents) must be returned to and approved by PCCD for the requested funding to be awarded.
- **Non-supplantation** – Funding must not be used to supplant/replace state, federal, or local funds that would otherwise be available to provide for program-related services. PCCD funding is to be used in addition to other funds that are made available for services.

PENNSYLVANIA COMMISSION ON CRIME AND DELINQUENCY
Office of Justice Programs

1. Overview:

This is a noncompetitive funding announcement open to the 61 counties in Pennsylvania with a county jail. The Pennsylvania Commission on Crime and Delinquency (PCCD) is now accepting applications for funding under the 2026 Medication-Assisted Substance Use Treatment Grant Program. The primary purpose of this funding is to support counties seeking to increase opportunities to provide Medication-Assisted Treatment (MAT), in combination with comprehensive substance use disorder treatment, to eligible offenders who meet the clinical criteria for an opioid use disorder or an alcohol use disorder, as determined by a physician, while incarcerated and upon release from a county jail. For purposes of this funding announcement, the term "Medication-Assisted Treatment" means the use of United States Food and Drug Administration-approved medications (buprenorphine, methadone, and naltrexone/Vivitrol), together with nonmedication treatment, as clinically indicated, to treat substance use disorders, including opioid use disorders and alcohol use disorders. Administration of these medications along with comprehensive substance use disorder treatment will allow newly released participants to focus on immediate reentry needs.

Funded counties will adhere to program activities and requirements as discussed in this funding announcement and work collaboratively with local and state partners to ensure effective program operations and successful project outcomes.

Successful projects will allow county jails to better equip reentrants as they transition to the community.

2. Funding Availability:

Approximately \$7.7 million in state Act 80 funds is being announced to support this initiative. PCCD expects to fund 61 grants with budgets not to exceed \$250,000 over a 24-month project period.

Allocations for the 61 eligible counties are included in *Appendix A* starting on page 13 of the funding announcement. The allocation formula includes a \$75,000 base award for all counties with a jail and incorporates each county's average jail population, jail admissions, and overdose death rate per 10,000 residents up to a maximum award amount of \$250,000.

Please note, future formulas and allocations for Act 80 funds will vary and will be contingent upon the availability of funds. Counties should not expect to receive similar allocation amounts in the future.

PCCD is not liable for costs incurred prior to the official start date of the award.

3. Project Dates:

Applications approved at the March 11, 2026, Commission meeting will be 24-month projects and have a start date of April 1, 2026, and an end date of March 31, 2028. Applications approved at the June 10, 2026, Commission meeting will be 24-month projects and have a start date of July 1, 2026, and an end date of June 30, 2028.

4. Eligible Applicants:

Eligibility for these funds is open to all counties with a county jail seeking to establish or expand a jail-based substance use treatment program that supports individuals transitioning from a county jail to the community or individuals who are sentenced to serve probation with restrictive conditions sentences. Eligible applicants are required to contract with an entity, provider(s), or organization(s) that shall:

- Provide an appropriate individual assessment prior to reentry into the community and determine if the individual is an appropriate candidate for participation in this program;
- Create an individualized program for each appropriate candidate;
- Provide access to and administer United States Food and Drug Administration-approved medications (buprenorphine, methadone, and naltrexone/Vivitrol);
- Provide clinically appropriate inpatient or outpatient services determined as necessary to support treatment plans;
- Cooperate with the county probation and parole offices as to the use of any drug by eligible participants; and
- Create a discharge plan for everyone.

Applicants must be in good standing with PCCD to be eligible for these funds.¹ The applicant and recipient agencies' historical success in implementing PCCD-funded programs/initiatives that met their intended goals will be considered in the review process. Applicants are not required to have a prior funding history with PCCD to be eligible.

5. Eligible Program Activities and Expenses:

Funds for the proposed program may be used for, but are not limited to, the following eligible activities and expenses:

- a. Implementation and/or expansion of a county jail-based MAT program through a contracted entity, provider(s), or organization(s). In addition to the requirements for an entity, provider(s), or organization(s) set forth in the Eligible Applicants section, the following required protocols must be established for all programs:
 - Programs must provide ongoing education regarding United States Food and Drug Administration-approved medications (buprenorphine, methadone, and naltrexone/Vivitrol) and refer interested individuals to relevant staff for eligibility determination.
 - Programs must order labs (ALT, AST, BUN, and Creatinine) to ensure individuals are not experiencing liver failure and do not have acute hepatitis or other liver conditions.
 - Prior to medication administration, programs must provide an instant drug screen and an instant pregnancy test (for females) and administer medications only for participants whose results are negative.

Additionally, the following protocols are strongly encouraged for all programs:

- Programs should continue to provide MAT to individuals with a valid prescription and induct individuals on MAT who meet the clinical criteria for an opioid use disorder or an alcohol use disorder, as determined by a physician.
- If utilizing naltrexone/Vivitrol, programs are encouraged to provide multiple injections prior to release. Note: all injections given inside the jail must be paid for with grant funding.
- Programs should assist participants with applications for Medicaid benefits, if eligible.

¹ This may include, but is not limited to, compliance with PCCD program and fiscal reporting requirements, State and Federal funding guidelines, and acceptable risk rating as determined by PCCD.

- Programs should contract with a licensed drug and alcohol provider within the community to deliver treatment services.
- Programs should work with participants to schedule all necessary community-based appointments (e.g., counseling services, monthly injections, etc.) prior to release.
- b. Cost of United States Food and Drug Administration-approved medications for participants in county jails.
- c. Evidence-based psychosocial treatment programming for justice-involved populations.
- d. County jail personnel costs to assist in administering the program.
- e. Travel expenses for staff to attend required training and technical assistance activities.

For purposes of this funding announcement, eligible program participants are limited to individuals convicted of a criminal offense who will be committed to the custody of the county and who meets the clinical criteria for an opioid or alcohol use disorder as determined by a physician. Each participant must agree to waive the privacy requirements of the Health Insurance Portability and Accountability Act of 1996 (Public Law 104-191, 110 Stat. 1936) to the extent needed for the county to have access to the information required by state law.

All expenses must be described in the Justification box located in the Egrants Budget Detail section. PCCD has approval of all final budgets and may require budget adjustments.

6. Ineligible Program Activities and Expenses:

The following activities are not eligible for funding and shall be administratively rejected:

- a. Land acquisition;
- b. Construction; or
- c. Any activities or expenses that do not relate directly to increasing opportunities for counties to program MAT in combination with comprehensive substance use disorder treatment.

7. Required Egrants Sections/Documents:

- a. Required Egrants Sections – All sections identified in Egrants are required. Applicants will not be able to submit their grant application in Egrants until all sections are marked as complete.
- b. Required Attachments – Please see “Required Attachments” on page 9 of the funding announcement for information about documents that must be uploaded in Egrants as part of the application.

8. Application Procedures:

Applicants must submit the requested information for each section specified below within the defined response fields provided in Egrants. Responses should not be duplicated in multiple sections.

The following application sections in Egrants are required as described below:

a. Executive Summary

All applicants should fill out the following script and paste into the executive summary section:

The name of applicant is requesting \$_____ to [provide a single sentence or two of what you are seeking to implement with your grant funding].

These funds will be used for the following: [provide bullet points of what the funds will be used for].

b. Budget Detail

The budget detail section should identify what the funds will be used for, and line items should be entered for each budgeted cost. Calculations should be clear and entered as the Egrants system requires in the budget detail section.

For any budgeted cost that is not self-explanatory, clearly explain the relationship between the budgeted costs and the proposed project activities/operation. Describe how the item will be used in the implementation of the proposed project. This section may include additional explanation of the computations stated in the Budget Detail section; however, computations provided within the line items should not be replicated in the justification field(s).

** Items should only be listed under the Equipment category if the cost of one item is \$10,000 or greater. Items with a cost of less than \$10,000 should be listed under Supplies and Operating Expenses.

NOTE: PCCD has final approval of all budgets and may require budget adjustments. Grantees may only request reimbursement for expenses that are clearly articulated and approved in the Budget detail in Egrants.

You can learn more about completing the Budget Detail section in Egrants in the 'Budget Detail Walkthrough' (PDF) available [here](#).

c. Statement of Problem

Provide an accurate assessment of the problem. Supporting data/facts/figures must be specific to your project's geographic area and relevant to the problem and your proposed request. Proposed projects should demonstrate consistency between the scope of effort and the resources to be used in the project.

d. Project Description

Type of Program: Please provide responses to the following questions:

- a. Which of the following best describes your proposed project?
 - Brand new MAT program
 - Continuing an existing MAT program
 - Expanding an existing MAT program
- b. Please identify the United States Food and Drug Administration-approved medications that your proposed project will provide from the list below (select all that apply):
 - Buprenorphine
 - Methadone
 - Naltrexone/Vivitrol
- c. Please identify the methods of administering MAT that your proposed project will provide from the list below (select all that apply):
 - Continuation for individuals with a valid prescription

- Induction of individuals who meet the clinical criteria for an opioid use disorder or an alcohol use disorder, as determined by a physician
- Both

- d. If you are proposing funding for an existing program/initiative, please provide the number of individuals served annually by that program.
- e. If you are proposing to expand an existing program/initiative, please provide the number of additional individuals who will be reached/served through Act 80 funding over the life of the project.
- f. If you are proposing a new initiative, please provide the estimated number of individuals you expect to reach or serve over the life of the project.

Program Eligibility: Describe the mechanisms in place to determine eligibility for involvement in the MAT program.

Implementation Plan: Describe the plan for implementing the proposed MAT program. This description should include where and how medication will be administered; who will administer the medication; plans for addressing medication diversion; what additional comprehensive substance use treatment programming will be provided; how and who will track program participation data; and any other details necessary to clearly establish how this project will be successfully implemented. All MAT programs should have established policies and procedures. These documents must be included in the *Required Attachments* section.

Continuity of Care: Describe the plan to ensure continuity of care upon institutional release for all MAT program participants. This should include any reentry and aftercare services provided to individuals preparing to leave the county jail; how the program will assist participants with applications for Medicaid benefits, if eligible; and how the program will connect individuals with licensed drug and alcohol providers within the community to deliver treatment services and ensure all necessary community-based appointments (e.g. counseling services, medication administration, etc.) are scheduled prior to release. All proposed MAT programs should coordinate with the local Single County Authority to ensure continuity of care for program participants. A letter of support/collaboration with the SCA must be included in the *Required Attachments* section.

Timeline: Provide a timeline describing the activities to be completed and what work will be accomplished during the project period.

Plan for Hiring/Onboarding/Training/Contracting Key Personnel: For new positions that will be created and hired if a grant is awarded, please describe the process and criteria for recruiting, selecting, hiring, and onboarding those staff/consultants. Please describe the process for contracting for any key personnel, if applicable. As part of this discussion, applicants should describe any current workforce or staffing challenges they are experiencing, as well as strategies they have used to recruit and/or retain employees. Applicants should also describe any training, professional development, and support that will be provided to these key personnel.

Additional Funding Sources: Please state whether the applicant has received funding previously from PCCD or other sources to support the proposed MAT program. If applicable, counties that have previously received funding to support the MAT program must articulate the impact of those funds and distinguish how proposed activities would differ from or build upon/expand currently/Previously funded projects.

Sustainability: Describe, in detail, how you will continue to support the MAT program once the awarded grant funds expire. Describe the sustainability plan to include how ongoing support for this program will be generated and maintained; how commitments from key stakeholders necessary for successful sustainability of the program will be established; and identify sources of financial support once grant funding expires.

e. **Measurement of Program Outcomes**

This section establishes that the applicant has a clear understanding of the intent of the project and PCCD requirements. It should further show the applicant is able to collect and report data and has a reasonable method to measure the project's success and impact. This will include process and outcome measures. Please address the following items in this section:

- Discuss how the effects of the project will be assessed and how the overall impact will be gauged;
- Describe the process measures that will be used to monitor the implementation of the project;
- Establish intermediate outcomes that will be used to measure the success of the project and how they will be tracked (what data will be collected); and
- Describe the method, tools, and documentation that will be used to track process and outcome measures for program participants.

9. Required Attachments

The following documents must be attached in the "Required Attachments" section in Egrants:

1. Resumes/CVs of key personnel.
2. MAT Program Policies and Procedures
3. Required documentation of collaboration with/support of SCA.

In addition, while not required, applicants are strongly encouraged to utilize the "Required Attachments" section in Egrants to upload other relevant materials that can supplement information provided within the application.

10. Performance Measures:

Under this funding announcement, successful applicants are required to comply with all reporting, data collection, and evaluation requirements as prescribed by PCCD and state guidelines. Applicants are required to submit quarterly progress reports to PCCD via the Egrants system. Subgrant recipients under this funding announcement will be required to accept and report on the performance measures selected by the staff of the PCCD Office of Justice Programs that will fulfill state guidelines for the use of Act 80 funds and legislatively mandated reporting requirements. Subgrant recipients must complete the 2026 Medication-Assisted Substance Use Treatment Grant Program Quarterly Report section included in the quarterly program report in the PCCD Egrants system. The report questions are included in this funding announcement as *Appendix B* starting on page 14.

If utilizing Naltrexone/Vivitrol, additional reporting requirements include the following bullets and are based on data relevant to the funded project:

- Number of participants supported with grant funding who were newly enrolled in the program during this report period;
- Number of participants supported with grant funding who received at least one Vivitrol injection during this report period;

- Number of total Vivitrol injections provided to participants supported with grant funding during this report period;
- Number of participants supported with grant funding who successfully completed the Vivitrol treatment program during this report period;
- Number of participants supported with grant funding who transitioned from the county jail to the community during this report period;
- Number of participants supported with grant funding who have been reincarcerated (3-month, 6-month, 1-year follow-up after release from jail) due to committing an alleged drug and/or alcohol related criminal offense;
- Number of participants supported with grant funding with new arrests during this report period;
- Number of program staff trained during this report period;
- As of the first day of this grant period, the number of entities, providers, or organizations available to:
 - Provide an appropriate individual assessment prior to reentry into the community and determine if the individual is an appropriate candidate for participation in this program;
 - Create an individualized program for each appropriate candidate;
 - Provide access to and administer Vivitrol;
 - Provide clinically appropriate inpatient or outpatient services determined as necessary to support treatment plans;
 - Cooperate with the county probation and parole offices as to the use of any drug by eligible participants; and
 - Create a discharge plan for each individual.

PCCD will calculate recidivism rates for individuals participating in the Medication-Assisted Substance Use Treatment Grant Program. For the purposes of this solicitation, *recidivism* is defined as the first instance of any type of re-arrest or reincarceration after an individual is released into the community from county jails.

Successful applicants will be required to report the following data elements to PCCD on a quarterly basis:

- SID (State Identification Number)
- OTN (Offender Tracking Number) which led to incarceration
- Individual's First and Last Name
- Date of Birth
- Race and Ethnicity
- Admission and Release Dates
- Revocation (Y/N)
- Revocation Date and Outcome (e.g. State Prison)
- County Jail Re-admission Date

Subgrant recipients may want to develop additional performance measures that are specifically related to the activities outlined in their application and may track and report all measures on a quarterly basis through the PCCD Egrants system.

11. Competitive Bidding/Sole Source Procurement:

All procurement transactions shall be conducted in a manner that provides open and free competition. Grant recipients must follow the Procurement Standards section in PCCD's [Applicant's Manual](#).

Procurements by noncompetitive proposal are strongly discouraged and must demonstrate an economic benefit or lack of alternate resources to be justified. If a request is made, the prospective applicant must identify the request as a procurement by noncompetitive

proposal and provide a substantial justification for the request within their funding request (See PCCD's [Applicant's Manual](#) for Procurement by Noncompetitive Proposal Approval Procedure).

12. Administrative Requirements:

a. Egrants Agency and User Registration:

Prior to submitting a grant application, both the applicant agency and at least two users from the applicant agency must be registered in Egrants. Applicants are strongly advised to allow adequate time to work on application documents in Egrants prior to the submission deadline. Please go to the [Getting Started in Egrants](#) page on PCCD's website for further information.

b. Fiscal Accountability:

See the [Fiscal Accountability](#) page on PCCD's website for further information.

c. Time and Effort Reporting:

See the [Time and Effort Reports](#) page on PCCD's website for further information.

d. Grant Payments:

- Payments will not be released until all applicable special conditions on the grant award have been satisfied.
- All grantees are required, at a minimum, to submit quarterly fiscal reports. PCCD will only make payments to reimburse actual expenditures reported on the fiscal reports. An agency experiencing cash flow problems may submit fiscal reports monthly and PCCD will reimburse reported expenditures. Non-submission or late submission of the required reports will result in payment delays.
- ACH Payments:
 - All payments to grant recipients will be made through ACH.
 - Either before or at the time an application is submitted to PCCD, the applicant agency must [register as a Non-Procurement Vendor](#) with the Commonwealth of Pennsylvania.

e. Federal Transparency Act Certification:

This section is required for both state and federal funding streams. See the [Federal Applicants](#) page on PCCD's website for further information.

f. Reporting Requirements:

- Programmatic reports are due quarterly.
- Fiscal reports are due quarterly.
- Late submission of programmatic and fiscal reports may delay payments.
- All reports must be submitted through the Egrants system.

g. UCR Reporting:

Every criminal justice entity which is required to submit Uniform Crime Report (UCR) data and is participating in this project must submit UCR data to the Pennsylvania State Police. If a required entity is not submitting UCR data, they may be ineligible for funding.

13. PCCD Contact Information and Resources:

a. Staff Contacts:

Questions concerning this funding announcement may be directed to PCCD staff as follows:

- Program-related questions: Contact Jennifer Bowser at (717) 257-6255 or jennbowser@pa.gov.
- Fiscal or budgetary questions: Contact Crystal Lauver at (717) 265-8525 or crlauver@pa.gov.

b. Egrants Funding Announcement:
Log into the Egrants system and search under the “Funding Announcement” tab for 2026 Medication-Assisted Substance Use Treatment.

c. PCCD Guidelines and Documents:
Applicants should be familiar with the [Applicant’s Manual](#), grant application and administrative guides, and other documents common to PCCD’s grant application process, all of which are available on the [Funding and Grants Process](#) page of the PCCD website.

d. Egrants Technical Questions:
For any technical or system questions, contact and ask for the Egrants Help Desk at (717) 787-5887 or (800) 692-7292, or by emailing RA-eGrantsSupport@pa.gov.

e. PCCD Webmaster:
Please address any technical problems you may have with the website or online forms to the [PCCD Web Master](#).

f. Reporting Potential Fraud, Waste and Abuse:
Information about waste, fraud, abuse, conflict of interest, bribery, gratuity, or other similar misconduct, or whistleblower reprisal relating to a PCCD employee, program, contract or grant, may be reported to the PCCD Fraud Hotline at (717) 525-5031. For more information, visit the [Reporting Fraud, Waste and Abuse](#) page on PCCD’s website.

14. Submission Information:

To be considered at the March 11, 2026 Commission meeting, applications must be entered into Egrants **no later than Tuesday, January 13, 2026, by 11:59 PM**.

To be considered at the June 10, 2026 Commission meeting, applications must be entered into Egrants **no later than Thursday, April 16, 2026, by 11:59 PM**.

The grant application must be electronically signed within Egrants. To electronically sign the application, at least one person from your organization must have the E-signature role in Egrants. Please use the link below to access instructions which explain how to request the E-signature role.

[E-signature Access Request Instructions](#)

[E-signature Access Request Form](#) (This must be attached to your access request in Egrants)

Please note that you cannot request the e-signature role on behalf of someone else.

Appendix A

2026 Medication-Assisted Substance Use Treatment Grant Program Maximum County Allocations

County	Maximum Allocation	County	Maximum Allocation
Adams	\$ 97,960	Lancaster	\$ 158,456
Allegheny	\$ 250,000	Lawrence	\$ 132,605
Armstrong	\$ 109,205	Lebanon	\$ 113,281
Beaver	\$ 126,679	Lehigh	\$ 175,832
Bedford	\$ 100,957	Luzerne	\$ 151,037
Berks	\$ 162,843	Lycoming	\$ 110,623
Blair	\$ 135,824	McKean	\$ 84,331
Bradford	\$ 113,677	Mercer	\$ 125,741
Bucks	\$ 170,491	Mifflin	\$ 102,968
Butler	\$ 130,647	Monroe	\$ 133,017
Cambria	\$ 137,320	Montgomery	\$ 199,903
Carbon	\$ 91,006	Montour	\$ 142,382
Centre	\$ 95,280	Northampton	\$ 143,876
Chester	\$ 149,642	Northumberland	\$ 110,820
Clarion	\$ 94,672	Perry	\$ 83,569
Clearfield	\$ 114,331	Philadelphia	\$ 250,000
Clinton	\$ 99,946	Pike	\$ 116,518
Columbia	\$ 110,881	Potter	\$ 77,971
Crawford	\$ 111,092	Schuylkill	\$ 126,243
Cumberland	\$ 123,078	Somerset	\$ 100,563
Dauphin	\$ 180,765	Susquehanna	\$ 102,644
Delaware	\$ 208,230	Tioga	\$ 89,796
Elk	\$ 107,327	Union	\$ 79,763
Erie	\$ 165,759	Venango	\$ 109,298
Fayette	\$ 134,786	Warren	\$ 99,959
Franklin	\$ 112,327	Washington	\$ 122,544
Greene	\$ 101,584	Wayne	\$ 99,062
Huntingdon	\$ 90,099	Westmoreland	\$ 145,331
Indiana	\$ 106,619	Wyoming	\$ 80,085
Jefferson	\$ 90,708	York	\$ 177,577
Lackawanna	\$ 162,825		

Appendix B

2026 Medication-Assisted Substance Use Treatment Grant Program Quarterly Report

1. Total number of MAT program participants supported with Act 80 funds: _____
 - a. Number of participants supported with Act 80 funds already enrolled in the MAT program at the start of this reporting period: _____
 - b. Number of new participants supported with Act 80 funds enrolled in the MAT program during this reporting period: _____
2. Number of individuals in the county jail who screened positive for opioid use disorder or number of individuals who exhibited opioid withdrawal symptoms during this reporting period: _____
3. Number of participants supported with Act 80 funds who received the following treatments while incarcerated during this reporting period:
 - a. Buprenorphine taper: _____
 - b. Buprenorphine maintenance: _____
 - c. Methadone taper for withdrawal: _____
 - d. Methadone maintenance: _____
 - e. Extended Release Naltrexone (Vivitrol): _____
 - f. Non-medication therapies: _____
4. Number of participants supported with Act 80 funds who were actively receiving medication treatment before entry that were started on any of the following treatments during this reporting period:
 - a. Buprenorphine taper: _____
 - b. Buprenorphine maintenance: _____
 - c. Methadone taper for withdrawal: _____
 - d. Methadone maintenance: _____
 - e. Extended Release Naltrexone (Vivitrol): _____
 - f. Non-medication therapies: _____
5. Number of participants supported with Act 80 funds who were not actively in treatment before entry that were initiated on the following treatments during this reporting period:
 - a. Buprenorphine taper: _____
 - b. Buprenorphine maintenance: _____
 - c. Methadone taper for withdrawal: _____
 - d. Methadone maintenance: _____
 - e. Extended Release Naltrexone (Vivitrol): _____
 - f. Non-medication therapies: _____
6. Number of participants supported with Act 80 funds who successfully completed the MAT treatment program during this report period: _____
7. Of the number of participants supported with Act 80 funds who successfully completed the MAT treatment program during this reporting period, number of participants who were:
 - a. Released into the community: _____
 - b. Transitioned to another corrections facility: _____
 - c. Other, please explain: _____

8. Number of program participants who received the following aftercare services during this report period:
 - a. Referral/ Appointment with Opioid Treatment Program/Methadone program: _____
 - b. Referral/Appointment with buprenorphine provider: _____
 - c. Referral/Appointment to Non-medication therapy program: _____
 - d. Other aftercare services: _____
9. Number of program participants supported with Act 80 funds who received vocational training during this reporting period: _____
10. Number of participants supported with Act 80 funds who diverted their prescribed buprenorphine during this reporting period: _____
11. Number of conduct citations related to buprenorphine contraband during this reporting period: _____
12. Number of positive drug screens for non-prescribed opioid use during this reporting period: _____
13. Number of inmates who reported an assault related to diversion of buprenorphine during this reporting period: _____
14. Number of jail staff trained in an Evidence-Based Practice during the report period during this reporting period: _____